Ziopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Ziopharm’s Board of Directors


You May Also Like

Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology ...

Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference

MADISON, Wis., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused ...